Nature Biotechnology, Published online: 26 May 2026; doi:10.1038/s41587-026-03180-7
Author Correction: DNA-guided CRISPR–Cas12a effectors for programmable RNA recognition and cleavage
Improving multimodal wearable sensing for healthcare with artificial intelligence
Nature Biotechnology, Published online: 26 May 2026; doi:10.1038/s41587-026-03134-z
This Comment explores artificial intelligence-driven strategies to accelerate the clinical translation of multimodal wearable sensors. We outline key data-science challenges and highlight disease contexts in which these systems could support therapeutic interventions.
Programming biology: next-gen AI firms raise billions to design better medicines
Nature Biotechnology, Published online: 26 May 2026; doi:10.1038/s41587-026-03170-9
Faster drug discovery, optimized drug design, even programmable therapeutics: AI is impacting R&D. Data and development bottlenecks remain.
A framework for building a synthetic cell from the SynCell Asia Initiative
Nature Biotechnology, Published online: 26 May 2026; doi:10.1038/s41587-026-03153-w
Building a living cell from scratch requires overcoming a bottleneck that has remained unresolved despite decades of progress: orchestrating the spatiotemporal integration of core functional modules. To tackle this barrier, the SynCell Asia Initiative outlines a strategy for developing core functional modules followed by their systems-level integration through the establishment of a centralized, artificial intelligence (AI)-driven biofoundry.
Fetal monitoring for high-risk pregnancies using a wearable ultrasound patch
Nature Biotechnology, Published online: 26 May 2026; doi:10.1038/s41587-026-03140-1
A wearable ultrasound device is optimized for continuous monitoring of pregnancies.
Enabling secure discovery in trusted research environments with improved tooling
Nature Medicine, Published online: 26 May 2026; doi:10.1038/s41591-026-04401-x
Biobanks are introducing trusted research environments to enable secure data access, yet they can increase costs and complexity for biomedical researchers who use them. We discuss challenges and solutions and introduce the Python Phenofhy community tool for Our Future Health.
Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial
Nature Medicine, Published online: 26 May 2026; doi:10.1038/s41591-026-04376-9
In a multicenter phase 2 trial, the fibroblast growth factor receptor inhibitor rogaratinib showed encouraging clinical efficacy in patients with succinate dehydrogenase-deficient gastrointestinal stromal tumors, suggesting a potential new treatment option for this patient population and demonstrating that an epigenetic mechanism of oncogene activation can be successfully targeted with a tyrosine kinase inhibitor.
Microglial mitochondria transfer to astrocytes via GPNMB-enriched extracellular vesicles alleviates cognitive deficits in tauopathy mice
Nature Neuroscience, Published online: 26 May 2026; doi:10.1038/s41593-026-02317-w
In PS19 mice, microglia-derived glycoprotein nonmetastatic melanoma protein B promotes mitochondrial extracellular vesicle secretion, enabling mitochondrial transfer to astrocytes. This improves astrocytic function and reduces Alzheimer’s disease (AD) symptoms, while GPNMB deficiency impairs it, highlighting new AD treatment avenues.
<![CDATA[AI adoption in psychiatry and emerging psychedelic therapies are among the most anticipated topics at ASCP 2026, according to Benjamin Brody, MD.]]>
STAT+: Eli Lilly to buy three small vaccine developers
Eli Lilly said Tuesday it would buy three early- and mid-stage vaccine developers, a boost for the field.
The deals — which together could cost up to nearly $4 billion — are the latest acquisitions from Lilly, a company rich with cash from its booming GLP-1 business. In recent months, it’s picked up companies working on cancer, autoimmune diseases, and sleep disorders, all for under $10 billion each.
The companies being bought are Curevo, LimmaTech Biologics, and Vaccine Company.